W. Ray Kim, John J. Poterucha, Walter K. Kremers, Michael B. Ishitani, E. Rolland Dickson – 23 July 2004 – Important innovations, such as hepatitis B immune globulin (HBIG) and lamivudine, have been introduced to the care of patients undergoing liver transplantation (OLT) for viral hepatitis B (HBV) (over the last 15 years). We analyzed survival of OLT recipients with HBV in the United States to examine the effect of these innovations.

Peter Faybik, Claus‐Georg Krenn, Amir Baker, Daniel Lahner, Gabriela Berlakovich, Heinz Steltzer, Hubert Hetz – 23 July 2004 – Plasma disappearance rate of indocyanine green (PDRICG) has been proposed for assessment of liver function in liver transplants donors and recipients, in patients with chronic liver failure, and as a prognostic factor in critically ill patients. The assessment of PDRICG using a newly developed noninvasive digital pulse densitometry method was simultaneously compared to invasive aortic fiber‐optic method in patients undergoing orthotopic liver transplantation (OLT).

Ann S. Fulcher – 23 July 2004

John C. Bucuvalas, Lan Zeng, Ravinder Anand, The Studies of Pediatric Liver Transplantation (SPLIT) Research Group – 23 July 2004 – The resources that are directed towards the care of liver transplant recipients are substantial. Approximately 100 million dollars are spent on the hospitalization of the 400–500 children in the United States who undergo liver transplantation each year.

Jason M. Hui, Alex Hodge, Geoffrey C. Farrell, James G. Kench, Adamandia Kriketos, Jacob George – 30 June 2004 – Adiponectin has antilipogenic and anti‐inflammatory effects, while tumor necrosis factor α (TNF‐α) reduces insulin sensitivity and has proinflammatory effects.

Adeel A. Butt, Shawn L. Fultz, C. Kent Kwoh, David Kelley, Melissa Skanderson, Amy C. Justice – 30 June 2004 – We examined the association of hepatitis C virus (HCV) infection with diabetes in veterans infected with human immunodeficiency virus (HIV) before and after the institution of highly active antiretroviral therapy (HAART). The role of age, race, liver disease, alcohol, and drug diagnoses upon the risk of diabetes was also determined. Male veterans with HIV who entered care between 1992 and 2001 were identified from the Veterans Affairs (VA) administrative database.

Gavin E. Arteel – 30 June 2004 – Angiotensin II (AngII) is a pro‐oxidant and fibrogenic cytokine. We investigated the role of NADPH oxidase in AngII‐induced effects in hepatic stellate cells (HSCs), a fibrogenic cell type. Human HSCs express mRNAs of key components of nonphagocytic NADPH oxidase. AngII phosphorylated p47phox, a regulatory subunit of NADPH oxidase, and induced reactive oxygen species formation via NADPH oxidase activity. AngII phosphorylated AKT and MAPKs and increased AP‐1 DNA binding in a redox‐sensitive manner.

30 June 2004

James G. Orr, Val Leel, Gary A. Cameron, Carylyn J. Marek, Emma L. Haughton, Lucy J. Elrick, Julie E. Trim, Gabrielle M. Hawksworth, Andrew P. Halestrap, Matthew C. Wright – 30 June 2004 – Gliotoxin has been shown to promote a reversal of liver fibrosis in an animal model of the disease although its mechanism of action in the liver is poorly defined. The effects of gliotoxin on activated hepatic stellate cells (HSCs) and hepatocytes have therefore been examined.

Patrick Marcellin, Herve Mommeja‐Marin, Stephen L. Sacks, George K. K. Lau, Daniel Sereni, Jean‐Pierre Bronowicki, Brian Conway, Christian Trepo, M. Robert Blum, Byung Chul Yoo, Elsa Mondou, Jeff Sorbel, Andrea Snow, Franck Rousseau, Hyo‐Suk Lee – 30 June 2004 – Current therapies available for the treatment of chronic hepatitis B are limited in their ability to result in a cure. Clevudine is a new pyrimidine analog with potent anti‐hepatitis B virus (HBV) activity in vitro. A multicenter dose‐escalation study evaluated clevudine at 10, 50, 100, and 200 mg once daily for 28 days.